Sign Out
Fexofenadine does not undergo hepatic biotransformation and therefore will not interact with other drugs through hepatic mechanisms. Co-administration of Fexofenadine HCl with erythromycin or ketoconazole has been found to result in a 2-3 times increase in the level of Fexofenadine in plasma. The changes were not accompanied by any effects on the QT interval and were not associated with any increase in adverse events compared to the drugs given singly.
No interaction between Fexofenadine and omeprazole was observed. However, the administration of an antacid containing aluminium and magnesium hydroxide gels 15 min prior to Fexofenadine HCl caused a reduction in bioavailability, most likely due to binding in the gastrointestinal tract. It is advisable to leave two hrs between administration of Fexofenadine HCl and aluminium- and magnesium- hydroxide containing antacids.
